KMPharmaceutical shares on KOSDAQ remain halted pending court decision on delisting injunction challenge

• KMPharmaceutical’s KOSDAQ-listed common shares remain suspended from Sept. 15, 2026 under a Korea Exchange investor-protection halt.
• The suspension period was extended to cover any objection to a court injunction tied to a delisting dispute.
• Trading will stay halted until a court decision on the objection or a final ruling on the main case.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. KMPharmaceutical Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261002901108), on October 02, 2026, and is solely responsible for the information contained therein.